



Full wwPDB NMR Structure Validation Report ⓘ

Apr 15, 2026 – 11:22 AM UTC

PDB ID : 1AWO / pdb_00001awo
Title : THE SOLUTION NMR STRUCTURE OF ABL SH3 AND ITS RELATIONSHIP TO SH2 IN THE SH(32) CONSTRUCT, 20 STRUCTURES
Authors : Cowburn, D.
Deposited on : 1997-10-03

This is a Full wwPDB NMR Structure Validation Report for a publicly released PDB entry.

We welcome your comments at validation@mail.wwpdb.org

A user guide is available at

<https://www.wwpdb.org/validation/2017/NMRValidationReportHelp>

with specific help available everywhere you see the ⓘ symbol.

The types of validation reports are described at

<http://www.wwpdb.org/validation/2017/FAQs#types>.

The following versions of software and data (see [references ⓘ](#)) were used in the production of this report:

MolProbity	:	4-5-2 with Phenix2.0
Percentile statistics	:	20250101.v01 (using entries in the PDB archive January 1st 2025)
wwPDB-RCI	:	v_1n_11_5_13_A (Berjanski et al., 2005)
PANAV	:	Wang et al. (2010)
wwPDB-ShiftChecker	:	v1.2
Ideal geometry (proteins)	:	Engh & Huber (2001)
Ideal geometry (DNA, RNA)	:	Parkinson et al. (1996)
Validation Pipeline (wwPDB-VP)	:	2.49


1 Overall quality at a glance

The following experimental techniques were used to determine the structure:

SOLUTION NMR

The overall completeness of chemical shifts assignment was not calculated.

Percentile scores (ranging between 0-100) for global validation metrics of the entry are shown in the following graphic. The table shows the number of entries on which the scores are based.



Metric	Whole archive (#Entries)	NMR archive (#Entries)
Clashscore	229148	14424
Ramachandran outliers	224038	12848
Sidechain outliers	223484	12823

The table below summarises the geometric issues observed across the polymeric chains and their fit to the experimental data. The red, orange, yellow and green segments indicate the fraction of residues that contain outliers for ≥ 3 , 2, 1 and 0 types of geometric quality criteria. A cyan segment indicates the fraction of residues that are not part of the well-defined cores, and a grey segment represents the fraction of residues that are not modelled. The numeric value for each fraction is indicated below the corresponding segment, with a dot representing fractions $\leq 5\%$

Mol	Chain	Length	Quality of chain
1	A	62	24% 52% 15% • 8%

2 Ensemble composition and analysis

This entry contains 20 models. Model 7 is the overall representative, medoid model (most similar to other models).

The following residues are included in the computation of the global validation metrics.

Well-defined (core) protein residues			
Well-defined core	Residue range (total)	Backbone RMSD (Å)	Medoid model
1	A:65-A:120 (56)	0.99	7

Ill-defined regions of proteins are excluded from the global statistics.

Ligands and non-protein polymers are included in the analysis.

The models can be grouped into 1 clusters. No single-model clusters were found.

Cluster number	Models
1	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

3 Entry composition

There is only 1 type of molecule in this entry. The entry contains 867 atoms, of which 423 are hydrogens and 0 are deuteriums.

- Molecule 1 is a protein called ABL TYROSINE KINASE.

Mol	Chain	Residues	Atoms						Trace
1	A	57	Total	C	H	N	O	S	0
			867	282	423	74	87	1	

There are 7 discrepancies between the modelled and reference sequences:


Chain	Residue	Modelled	Actual	Comment	Reference
A	59	GLY	SER	conflict	UNP P00519
A	60	SER	GLU	conflict	UNP P00519
A	61	PRO	ASN	conflict	UNP P00519
A	62	GLY	ASP	conflict	UNP P00519
A	63	GLY	PRO	conflict	UNP P00519
A	64	SER	ASN	conflict	UNP P00519
A	120	SER	ASN	conflict	UNP P00519

4 Residue-property plots [i](#)

4.1 Average score per residue in the NMR ensemble

These plots are provided for all protein, RNA, DNA and oligosaccharide chains in the entry. The first graphic is the same as shown in the summary in section 1 of this report. The second graphic shows the sequence where residues are colour-coded according to the number of geometric quality criteria for which they contain at least one outlier: green = 0, yellow = 1, orange = 2 and red = 3 or more. Stretches of 2 or more consecutive residues without any outliers are shown as green connectors. Residues which are classified as ill-defined in the NMR ensemble, are shown in cyan with an underline colour-coded according to the previous scheme. Residues which were present in the experimental sample, but not modelled in the final structure are shown in grey.

- Molecule 1: ABL TYROSINE KINASE




4.2 Scores per residue for each member of the ensemble

Colouring as in section 4.1 above.


4.2.1 Score per residue for model 1

- Molecule 1: ABL TYROSINE KINASE




4.2.2 Score per residue for model 2

- Molecule 1: ABL TYROSINE KINASE




4.2.3 Score per residue for model 3

- Molecule 1: ABL TYROSINE KINASE




4.2.4 Score per residue for model 4

- Molecule 1: ABL TYROSINE KINASE




4.2.5 Score per residue for model 5

- Molecule 1: ABL TYROSINE KINASE




4.2.6 Score per residue for model 6

- Molecule 1: ABL TYROSINE KINASE




4.2.7 Score per residue for model 7 (medoid)

- Molecule 1: ABL TYROSINE KINASE




4.2.8 Score per residue for model 8

- Molecule 1: ABL TYROSINE KINASE




4.2.9 Score per residue for model 9

- Molecule 1: ABL TYROSINE KINASE




4.2.10 Score per residue for model 10

- Molecule 1: ABL TYROSINE KINASE




4.2.11 Score per residue for model 11


- Molecule 1: ABL TYROSINE KINASE



4.2.12 Score per residue for model 12

- Molecule 1: ABL TYROSINE KINASE






4.2.18 Score per residue for model 18

- Molecule 1: ABL TYROSINE KINASE

Chain A: 35% 37% 15% . . 8%



4.2.19 Score per residue for model 19

- Molecule 1: ABL TYROSINE KINASE

Chain A: 42% 31% 18% . 8%



4.2.20 Score per residue for model 20

- Molecule 1: ABL TYROSINE KINASE

Chain A: 27% 45% 16% . . 8%



5 Refinement protocol and experimental data overview

The models were refined using the following method: *VARIABLE TARGET FUNCTION TORSION ANGLE SIMULATED ANNEALING*.

Of the 100 calculated structures, 20 were deposited, based on the following criterion: *LOWEST TARGET FUNCTION*.

The following table shows the software used for structure solution, optimisation and refinement.

Software name	Classification	Version
DIANA	refinement	2.1
RUNMR	structure solution	
UXNMR	structure solution	
DIANA (REDAC)	structure solution	(REDAC)

No chemical shift data was provided.

6 Model quality

6.1 Standard geometry

There are no covalent bond-length or bond-angle outliers.

There are no bond-length outliers.

There are no bond-angle outliers.

There are no chirality outliers.

There are no planarity outliers.

6.2 Too-close contacts

In the following table, the Non-H and H(model) columns list the number of non-hydrogen atoms and hydrogen atoms in each chain respectively. The H(added) column lists the number of hydrogen atoms added and optimized by MolProbity. The Clashes column lists the number of clashes averaged over the ensemble.

Mol	Chain	Non-H	H(model)	H(added)	Clashes
1	A	438	418	418	40±6
All	All	8760	8360	8360	793

The all-atom clashscore is defined as the number of clashes found per 1000 atoms (including hydrogen atoms). The all-atom clashscore for this structure is 46.

All unique clashes are listed below, sorted by their clash magnitude.

Atom-1	Atom-2	Clash(Å)	Distance(Å)	Models	
				Worst	Total
1:A:69:LEU:HD13	1:A:117:THR:HG23	1.04	1.29	9	2
1:A:68:ALA:HB2	1:A:88:LEU:HD23	1.01	1.06	9	2
1:A:82:ILE:HD13	1:A:88:LEU:CD1	0.95	1.91	19	2
1:A:68:ALA:HB2	1:A:88:LEU:HD22	0.93	1.36	5	11
1:A:80:LEU:HD22	1:A:82:ILE:CD1	0.90	1.96	4	5
1:A:68:ALA:HB2	1:A:88:LEU:CD2	0.89	1.96	9	3
1:A:72:PHE:CE1	1:A:74:ALA:HB3	0.88	2.03	20	2
1:A:72:PHE:CZ	1:A:74:ALA:HB2	0.87	2.04	13	1
1:A:80:LEU:HD22	1:A:82:ILE:CG1	0.85	2.00	2	4
1:A:80:LEU:HD13	1:A:108:GLN:O	0.85	1.71	8	1
1:A:82:ILE:HG21	1:A:88:LEU:HD12	0.84	1.49	19	2
1:A:67:VAL:O	1:A:116:ILE:HG23	0.84	1.70	1	5
1:A:80:LEU:HD12	1:A:108:GLN:C	0.83	1.97	9	7
1:A:65:LEU:O	1:A:119:VAL:HG23	0.83	1.72	11	12

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Clash(Å)	Distance(Å)	Models	
				Worst	Total
1:A:68:ALA:CB	1:A:88:LEU:HD23	0.82	1.99	9	1
1:A:72:PHE:CZ	1:A:74:ALA:HB3	0.82	2.10	20	1
1:A:82:ILE:HD12	1:A:88:LEU:HD11	0.81	1.50	3	1
1:A:88:LEU:C	1:A:88:LEU:HD23	0.81	2.00	19	11
1:A:91:LEU:HD12	1:A:103:GLN:OE1	0.80	1.76	16	2
1:A:90:VAL:HG11	1:A:93:TYR:CE2	0.80	2.11	7	1
1:A:82:ILE:HD13	1:A:88:LEU:HD13	0.79	1.52	12	1
1:A:82:ILE:HB	1:A:88:LEU:HD11	0.77	1.54	16	2
1:A:80:LEU:HD22	1:A:82:ILE:HD13	0.77	1.55	17	2
1:A:80:LEU:HD21	1:A:104:THR:HG21	0.76	1.55	6	5
1:A:88:LEU:HD23	1:A:88:LEU:O	0.74	1.82	1	5
1:A:80:LEU:HD21	1:A:104:THR:CG2	0.73	2.13	2	5
1:A:80:LEU:HD21	1:A:104:THR:OG1	0.73	1.83	18	5
1:A:80:LEU:CD2	1:A:104:THR:HG21	0.72	2.14	1	1
1:A:80:LEU:HD12	1:A:109:GLY:N	0.71	2.01	6	4
1:A:69:LEU:HD13	1:A:117:THR:CG2	0.71	2.15	9	1
1:A:102:ALA:HB3	1:A:111:VAL:HG11	0.71	1.62	1	4
1:A:73:VAL:HG13	1:A:74:ALA:N	0.71	2.01	4	1
1:A:68:ALA:HA	1:A:116:ILE:HG23	0.70	1.63	3	1
1:A:119:VAL:HG22	1:A:120:SER:N	0.70	2.02	13	2
1:A:68:ALA:HB2	1:A:88:LEU:HB3	0.69	1.63	2	10
1:A:82:ILE:HG22	1:A:86:GLU:OE2	0.68	1.88	10	1
1:A:111:VAL:HG13	1:A:116:ILE:HD11	0.68	1.63	13	3
1:A:82:ILE:HG21	1:A:88:LEU:CD1	0.68	2.18	19	2
1:A:68:ALA:HA	1:A:116:ILE:HG22	0.67	1.63	14	1
1:A:91:LEU:HD13	1:A:103:GLN:CD	0.67	2.15	8	2
1:A:94:ASN:ND2	1:A:110:TRP:CZ3	0.67	2.63	6	6
1:A:72:PHE:CE1	1:A:74:ALA:HB2	0.66	2.25	9	1
1:A:80:LEU:HD12	1:A:109:GLY:C	0.66	2.14	12	2
1:A:82:ILE:HD13	1:A:88:LEU:HD11	0.66	1.67	19	1
1:A:102:ALA:HB3	1:A:111:VAL:CG1	0.66	2.21	15	4
1:A:94:ASN:ND2	1:A:110:TRP:CH2	0.65	2.63	17	5
1:A:82:ILE:HD12	1:A:104:THR:HG21	0.65	1.69	17	2
1:A:80:LEU:HD12	1:A:108:GLN:O	0.64	1.93	13	3
1:A:90:VAL:CG2	1:A:116:ILE:HD12	0.64	2.22	2	1
1:A:115:TYR:O	1:A:116:ILE:HD13	0.64	1.93	12	2
1:A:80:LEU:HD22	1:A:82:ILE:HG12	0.63	1.70	15	3
1:A:82:ILE:HD11	1:A:111:VAL:CG2	0.63	2.23	19	1
1:A:93:TYR:CD1	1:A:93:TYR:N	0.63	2.67	5	3
1:A:102:ALA:HB2	1:A:111:VAL:HG11	0.63	1.71	3	2
1:A:80:LEU:HD22	1:A:82:ILE:HD12	0.63	1.69	7	2

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Clash(Å)	Distance(Å)	Models	
				Worst	Total
1:A:96:ASN:O	1:A:97:GLY:C	0.63	2.40	7	5
1:A:104:THR:HG22	1:A:106:ASN:H	0.63	1.52	12	3
1:A:69:LEU:HD12	1:A:117:THR:CG2	0.63	2.24	14	8
1:A:68:ALA:HB3	1:A:86:GLU:O	0.62	1.94	1	1
1:A:82:ILE:CD1	1:A:88:LEU:HD21	0.62	2.24	15	2
1:A:72:PHE:CE2	1:A:80:LEU:O	0.62	2.52	2	1
1:A:72:PHE:HB3	1:A:82:ILE:HD12	0.62	1.71	13	1
1:A:72:PHE:CZ	1:A:74:ALA:CB	0.62	2.83	20	1
1:A:88:LEU:CD2	1:A:88:LEU:C	0.61	2.72	2	1
1:A:119:VAL:HG12	1:A:120:SER:N	0.61	2.10	10	6
1:A:72:PHE:CE1	1:A:73:VAL:O	0.61	2.53	15	4
1:A:94:ASN:OD1	1:A:110:TRP:CH2	0.61	2.53	16	1
1:A:72:PHE:CZ	1:A:80:LEU:O	0.61	2.54	2	1
1:A:72:PHE:CD2	1:A:80:LEU:O	0.61	2.54	2	1
1:A:72:PHE:CZ	1:A:73:VAL:O	0.61	2.53	12	1
1:A:80:LEU:HD12	1:A:109:GLY:O	0.61	1.94	15	2
1:A:82:ILE:HD13	1:A:88:LEU:HD21	0.61	1.72	16	2
1:A:88:LEU:C	1:A:88:LEU:CD2	0.60	2.74	5	10
1:A:93:TYR:CE2	1:A:100:CYS:SG	0.60	2.94	16	2
1:A:95:HIS:CG	1:A:96:ASN:N	0.60	2.70	4	1
1:A:72:PHE:CD1	1:A:80:LEU:O	0.60	2.55	15	2
1:A:94:ASN:CG	1:A:95:HIS:N	0.60	2.59	4	2
1:A:94:ASN:O	1:A:95:HIS:CB	0.59	2.49	4	4
1:A:80:LEU:HD11	1:A:104:THR:OG1	0.59	1.97	17	1
1:A:111:VAL:CG2	1:A:116:ILE:CD1	0.59	2.79	9	4
1:A:72:PHE:CE1	1:A:80:LEU:O	0.59	2.55	2	1
1:A:69:LEU:CD1	1:A:117:THR:HG21	0.59	2.26	15	4
1:A:84:LYS:O	1:A:85:GLY:C	0.59	2.43	7	19
1:A:82:ILE:HD11	1:A:111:VAL:HG23	0.59	1.73	19	1
1:A:72:PHE:CE1	1:A:74:ALA:CB	0.59	2.85	20	1
1:A:82:ILE:HD12	1:A:88:LEU:CD1	0.59	2.25	3	2
1:A:79:THR:HG23	1:A:80:LEU:N	0.58	2.13	14	13
1:A:72:PHE:CZ	1:A:79:THR:CG2	0.58	2.86	4	2
1:A:90:VAL:HG13	1:A:100:CYS:SG	0.58	2.39	13	1
1:A:72:PHE:CG	1:A:80:LEU:O	0.58	2.56	2	6
1:A:94:ASN:ND2	1:A:99:TRP:O	0.57	2.36	7	3
1:A:111:VAL:HG23	1:A:116:ILE:CD1	0.57	2.30	1	4
1:A:72:PHE:CE1	1:A:79:THR:HG21	0.57	2.34	10	2
1:A:95:HIS:CD2	1:A:95:HIS:N	0.57	2.71	11	1
1:A:104:THR:O	1:A:105:LYS:C	0.57	2.47	8	13
1:A:111:VAL:CG2	1:A:116:ILE:HD11	0.57	2.29	19	2

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Clash(Å)	Distance(Å)	Models	
				Worst	Total
1:A:69:LEU:HD22	1:A:70:TYR:CE2	0.56	2.36	4	1
1:A:80:LEU:CD1	1:A:108:GLN:C	0.56	2.78	19	4
1:A:72:PHE:CB	1:A:82:ILE:HD12	0.56	2.30	14	1
1:A:66:PHE:CD1	1:A:66:PHE:N	0.56	2.72	9	16
1:A:69:LEU:CD1	1:A:117:THR:CG2	0.56	2.84	14	6
1:A:69:LEU:HD12	1:A:117:THR:HG22	0.56	1.76	12	2
1:A:88:LEU:HD23	1:A:89:ARG:N	0.55	2.17	4	2
1:A:72:PHE:CZ	1:A:79:THR:HG23	0.55	2.37	15	2
1:A:84:LYS:CD	1:A:84:LYS:C	0.55	2.79	7	3
1:A:80:LEU:CD1	1:A:109:GLY:N	0.55	2.70	6	3
1:A:90:VAL:HG21	1:A:116:ILE:CD1	0.55	2.30	2	1
1:A:72:PHE:HB2	1:A:82:ILE:HD12	0.55	1.77	14	2
1:A:74:ALA:HB3	1:A:79:THR:HG21	0.55	1.77	13	2
1:A:69:LEU:HD12	1:A:117:THR:HG21	0.55	1.79	15	3
1:A:72:PHE:CD1	1:A:73:VAL:N	0.55	2.75	10	4
1:A:82:ILE:HG21	1:A:88:LEU:HD13	0.55	1.77	12	1
1:A:71:ASP:CG	1:A:72:PHE:N	0.55	2.65	12	2
1:A:94:ASN:OD1	1:A:95:HIS:CG	0.54	2.60	10	1
1:A:72:PHE:CE1	1:A:79:THR:CG2	0.54	2.90	14	3
1:A:94:ASN:O	1:A:95:HIS:CD2	0.54	2.60	16	1
1:A:114:ASN:OD1	1:A:115:TYR:CD1	0.54	2.61	9	2
1:A:72:PHE:CZ	1:A:79:THR:HG21	0.54	2.38	4	1
1:A:72:PHE:CE1	1:A:81:SER:HA	0.54	2.38	3	1
1:A:96:ASN:ND2	1:A:97:GLY:N	0.54	2.55	12	1
1:A:90:VAL:CG2	1:A:116:ILE:HG21	0.54	2.33	13	1
1:A:115:TYR:C	1:A:116:ILE:HD13	0.54	2.26	3	1
1:A:71:ASP:N	1:A:71:ASP:OD1	0.54	2.41	8	2
1:A:80:LEU:HD22	1:A:82:ILE:HD11	0.53	1.78	2	1
1:A:68:ALA:CA	1:A:116:ILE:HG23	0.53	2.33	3	1
1:A:72:PHE:CZ	1:A:81:SER:OG	0.53	2.61	3	1
1:A:94:ASN:OD1	1:A:96:ASN:N	0.53	2.42	7	3
1:A:69:LEU:HD12	1:A:117:THR:HB	0.53	1.81	14	3
1:A:94:ASN:O	1:A:95:HIS:CG	0.52	2.62	2	2
1:A:69:LEU:HB2	1:A:117:THR:HG22	0.52	1.81	2	1
1:A:79:THR:CG2	1:A:80:LEU:N	0.52	2.72	2	15
1:A:119:VAL:HG13	1:A:120:SER:H	0.52	1.65	7	2
1:A:104:THR:N	1:A:107:GLY:O	0.52	2.41	6	4
1:A:119:VAL:O	1:A:119:VAL:HG12	0.52	2.05	16	12
1:A:72:PHE:CE2	1:A:79:THR:CG2	0.52	2.93	4	1
1:A:90:VAL:HG11	1:A:93:TYR:CE1	0.52	2.39	15	2
1:A:110:TRP:C	1:A:111:VAL:CG1	0.52	2.83	5	5

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Clash(Å)	Distance(Å)	Models	
				Worst	Total
1:A:73:VAL:CG1	1:A:74:ALA:N	0.52	2.71	4	1
1:A:99:TRP:CZ3	1:A:112:PRO:HD3	0.52	2.40	2	11
1:A:104:THR:CG2	1:A:108:GLN:O	0.52	2.58	8	1
1:A:99:TRP:CE3	1:A:111:VAL:C	0.52	2.88	2	1
1:A:73:VAL:HG22	1:A:73:VAL:O	0.52	2.05	16	1
1:A:72:PHE:CZ	1:A:112:PRO:HD3	0.51	2.41	9	1
1:A:93:TYR:CD2	1:A:100:CYS:SG	0.51	3.04	15	1
1:A:94:ASN:OD1	1:A:99:TRP:O	0.51	2.29	5	2
1:A:88:LEU:HD12	1:A:103:GLN:O	0.51	2.05	9	1
1:A:90:VAL:HG21	1:A:100:CYS:SG	0.51	2.46	10	1
1:A:66:PHE:HE2	1:A:93:TYR:HH	0.51	1.45	8	1
1:A:80:LEU:HD22	1:A:82:ILE:HG13	0.51	1.81	16	4
1:A:91:LEU:HD12	1:A:103:GLN:HE22	0.51	1.64	6	1
1:A:72:PHE:CZ	1:A:81:SER:HA	0.51	2.41	3	1
1:A:91:LEU:HD12	1:A:103:GLN:HB2	0.51	1.83	3	1
1:A:69:LEU:HD22	1:A:70:TYR:CD2	0.51	2.41	4	1
1:A:98:GLU:CG	1:A:99:TRP:N	0.50	2.74	8	1
1:A:69:LEU:CD1	1:A:117:THR:HG23	0.50	2.21	9	1
1:A:67:VAL:CG1	1:A:119:VAL:CG2	0.50	2.89	8	1
1:A:90:VAL:HG21	1:A:116:ILE:HD12	0.50	1.82	2	1
1:A:86:GLU:OE2	1:A:105:LYS:CE	0.50	2.60	6	1
1:A:69:LEU:HD12	1:A:117:THR:CB	0.50	2.37	14	3
1:A:66:PHE:CD2	1:A:118:PRO:HB3	0.50	2.41	3	2
1:A:77:ASP:O	1:A:78:ASN:CB	0.50	2.58	15	2
1:A:95:HIS:O	1:A:95:HIS:CG	0.50	2.63	9	1
1:A:68:ALA:CB	1:A:88:LEU:HD22	0.49	2.35	16	2
1:A:119:VAL:CG2	1:A:120:SER:N	0.49	2.72	7	2
1:A:77:ASP:C	1:A:78:ASN:CG	0.49	2.80	13	5
1:A:65:LEU:O	1:A:119:VAL:CG2	0.49	2.59	15	6
1:A:102:ALA:HB2	1:A:111:VAL:CG1	0.49	2.36	3	2
1:A:72:PHE:CD1	1:A:81:SER:HA	0.49	2.42	3	2
1:A:66:PHE:CD2	1:A:90:VAL:HB	0.49	2.43	8	1
1:A:80:LEU:HD13	1:A:108:GLN:C	0.49	2.30	8	1
1:A:84:LYS:C	1:A:86:GLU:N	0.49	2.71	9	10
1:A:104:THR:O	1:A:107:GLY:O	0.49	2.29	12	4
1:A:94:ASN:O	1:A:95:HIS:C	0.49	2.56	11	5
1:A:72:PHE:CD1	1:A:72:PHE:C	0.49	2.91	12	2
1:A:80:LEU:CD2	1:A:81:SER:O	0.49	2.61	19	1
1:A:80:LEU:CD2	1:A:82:ILE:CD1	0.49	2.83	4	1
1:A:95:HIS:C	1:A:97:GLY:N	0.49	2.70	4	1
1:A:80:LEU:HD12	1:A:109:GLY:H	0.49	1.67	6	1

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Clash(Å)	Distance(Å)	Models	
				Worst	Total
1:A:69:LEU:HG	1:A:117:THR:HG21	0.49	1.85	16	1
1:A:83:THR:O	1:A:88:LEU:CD1	0.49	2.61	16	1
1:A:98:GLU:HG3	1:A:99:TRP:CD1	0.49	2.43	11	1
1:A:80:LEU:HD12	1:A:108:GLN:CA	0.49	2.37	17	1
1:A:66:PHE:CD1	1:A:118:PRO:HB3	0.48	2.43	11	3
1:A:67:VAL:C	1:A:116:ILE:HG23	0.48	2.33	1	1
1:A:112:PRO:HG2	1:A:115:TYR:CD1	0.48	2.43	2	5
1:A:100:CYS:O	1:A:111:VAL:HG12	0.48	2.08	4	2
1:A:74:ALA:HB3	1:A:79:THR:CG2	0.48	2.38	13	1
1:A:94:ASN:OD1	1:A:97:GLY:N	0.48	2.47	15	2
1:A:99:TRP:CH2	1:A:112:PRO:HG3	0.48	2.43	1	4
1:A:65:LEU:C	1:A:66:PHE:CD1	0.48	2.92	11	2
1:A:65:LEU:HD11	1:A:89:ARG:HD3	0.48	1.86	14	1
1:A:81:SER:C	1:A:82:ILE:HD13	0.48	2.34	4	1
1:A:84:LYS:CE	1:A:84:LYS:C	0.48	2.87	5	1
1:A:102:ALA:CB	1:A:111:VAL:HG11	0.48	2.39	19	3
1:A:67:VAL:HG22	1:A:119:VAL:HG22	0.48	1.86	3	2
1:A:72:PHE:CE2	1:A:79:THR:HG21	0.48	2.43	4	1
1:A:72:PHE:CE1	1:A:79:THR:HG23	0.48	2.43	6	5
1:A:76:GLY:C	1:A:77:ASP:CG	0.48	2.82	19	1
1:A:65:LEU:HD22	1:A:65:LEU:N	0.47	2.23	1	3
1:A:66:PHE:CD1	1:A:118:PRO:HA	0.47	2.44	17	1
1:A:73:VAL:HG12	1:A:73:VAL:O	0.47	2.09	20	1
1:A:67:VAL:N	1:A:117:THR:O	0.47	2.47	14	4
1:A:75:SER:N	1:A:79:THR:HG21	0.47	2.25	8	1
1:A:91:LEU:CD1	1:A:103:GLN:CD	0.47	2.85	8	1
1:A:82:ILE:HD12	1:A:82:ILE:H	0.47	1.69	1	3
1:A:95:HIS:O	1:A:96:ASN:CB	0.47	2.62	20	1
1:A:119:VAL:HG22	1:A:120:SER:H	0.47	1.68	7	2
1:A:88:LEU:O	1:A:88:LEU:CD2	0.47	2.61	1	1
1:A:77:ASP:O	1:A:78:ASN:C	0.47	2.57	16	9
1:A:113:SER:O	1:A:116:ILE:O	0.47	2.33	12	14
1:A:94:ASN:ND2	1:A:95:HIS:H	0.47	2.08	4	1
1:A:95:HIS:CE1	1:A:96:ASN:HB2	0.47	2.45	4	1
1:A:66:PHE:CD1	1:A:90:VAL:HB	0.47	2.45	10	2
1:A:111:VAL:HG22	1:A:116:ILE:HD11	0.47	1.87	19	1
1:A:112:PRO:HG2	1:A:115:TYR:CG	0.47	2.45	2	1
1:A:94:ASN:OD1	1:A:95:HIS:N	0.47	2.48	7	4
1:A:91:LEU:HD12	1:A:103:GLN:CD	0.47	2.35	18	1
1:A:80:LEU:CD2	1:A:104:THR:CG2	0.46	2.90	1	1
1:A:82:ILE:CD1	1:A:88:LEU:HD11	0.46	2.34	3	1

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Clash(Å)	Distance(Å)	Models	
				Worst	Total
1:A:111:VAL:HG23	1:A:112:PRO:HD2	0.46	1.88	16	2
1:A:67:VAL:CG1	1:A:119:VAL:HG22	0.46	2.40	8	1
1:A:66:PHE:O	1:A:89:ARG:CB	0.46	2.64	9	2
1:A:66:PHE:O	1:A:89:ARG:CG	0.46	2.63	20	1
1:A:84:LYS:O	1:A:86:GLU:N	0.46	2.49	6	10
1:A:96:ASN:O	1:A:96:ASN:CG	0.46	2.58	15	2
1:A:119:VAL:O	1:A:119:VAL:CG1	0.46	2.62	16	4
1:A:91:LEU:HD12	1:A:103:GLN:HB3	0.46	1.88	13	1
1:A:74:ALA:N	1:A:81:SER:OG	0.46	2.49	14	1
1:A:80:LEU:HD21	1:A:104:THR:HG22	0.46	1.86	2	1
1:A:80:LEU:CD2	1:A:82:ILE:HG12	0.46	2.41	2	1
1:A:69:LEU:CD1	1:A:117:THR:HG22	0.46	2.41	12	1
1:A:101:GLU:HG3	1:A:110:TRP:CD1	0.46	2.46	16	1
1:A:91:LEU:HD13	1:A:103:GLN:NE2	0.46	2.26	5	2
1:A:73:VAL:O	1:A:75:SER:N	0.46	2.49	3	3
1:A:76:GLY:O	1:A:77:ASP:CG	0.46	2.59	8	2
1:A:77:ASP:O	1:A:79:THR:N	0.46	2.49	18	1
1:A:95:HIS:O	1:A:96:ASN:C	0.45	2.60	14	2
1:A:80:LEU:HD12	1:A:109:GLY:CA	0.45	2.42	6	1
1:A:77:ASP:O	1:A:78:ASN:ND2	0.45	2.49	15	1
1:A:72:PHE:CD1	1:A:73:VAL:O	0.45	2.69	18	1
1:A:102:ALA:C	1:A:103:GLN:OE1	0.45	2.59	5	1
1:A:72:PHE:CG	1:A:73:VAL:N	0.45	2.83	15	1
1:A:93:TYR:CD1	1:A:100:CYS:HB3	0.45	2.46	7	1
1:A:90:VAL:CG1	1:A:100:CYS:SG	0.45	3.05	13	1
1:A:99:TRP:CZ2	1:A:112:PRO:HB3	0.45	2.45	1	2
1:A:113:SER:HA	1:A:116:ILE:HD11	0.45	1.86	2	2
1:A:94:ASN:OD1	1:A:95:HIS:CD2	0.45	2.70	10	1
1:A:81:SER:C	1:A:82:ILE:CG1	0.45	2.88	19	1
1:A:75:SER:CB	1:A:79:THR:HG21	0.45	2.42	2	1
1:A:90:VAL:HG23	1:A:116:ILE:HG21	0.45	1.89	13	2
1:A:96:ASN:ND2	1:A:98:GLU:OE2	0.45	2.50	3	1
1:A:94:ASN:OD1	1:A:94:ASN:C	0.45	2.60	15	2
1:A:96:ASN:O	1:A:98:GLU:N	0.45	2.49	7	2
1:A:82:ILE:CD1	1:A:88:LEU:HD12	0.45	2.41	8	1
1:A:77:ASP:O	1:A:78:ASN:CG	0.45	2.59	1	1
1:A:111:VAL:CG1	1:A:116:ILE:HD11	0.45	2.42	16	2
1:A:65:LEU:HD13	1:A:66:PHE:N	0.45	2.26	14	1
1:A:94:ASN:CG	1:A:99:TRP:O	0.44	2.60	12	1
1:A:76:GLY:O	1:A:77:ASP:O	0.44	2.34	14	3
1:A:65:LEU:HD13	1:A:65:LEU:C	0.44	2.37	14	1

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Clash(Å)	Distance(Å)	Models	
				Worst	Total
1:A:94:ASN:ND2	1:A:95:HIS:N	0.44	2.66	4	1
1:A:86:GLU:OE2	1:A:105:LYS:NZ	0.44	2.50	2	2
1:A:90:VAL:CG2	1:A:116:ILE:CD1	0.44	2.94	2	1
1:A:114:ASN:H	1:A:114:ASN:ND2	0.44	2.10	4	1
1:A:111:VAL:HG23	1:A:116:ILE:HD12	0.44	1.87	9	2
1:A:94:ASN:ND2	1:A:96:ASN:O	0.44	2.51	10	1
1:A:90:VAL:HG22	1:A:111:VAL:CG1	0.44	2.43	14	1
1:A:67:VAL:O	1:A:116:ILE:CG2	0.44	2.65	4	1
1:A:82:ILE:HD12	1:A:82:ILE:N	0.44	2.28	16	2
1:A:65:LEU:C	1:A:65:LEU:HD13	0.44	2.38	5	2
1:A:80:LEU:HD22	1:A:104:THR:HG21	0.44	1.87	1	1
1:A:82:ILE:CG2	1:A:86:GLU:OE2	0.44	2.61	10	1
1:A:84:LYS:HG2	1:A:85:GLY:N	0.43	2.28	2	1
1:A:101:GLU:OE2	1:A:108:GLN:CD	0.43	2.61	8	1
1:A:80:LEU:CD1	1:A:102:ALA:O	0.43	2.66	11	1
1:A:90:VAL:CG1	1:A:93:TYR:CE2	0.43	2.94	7	1
1:A:92:GLY:O	1:A:101:GLU:N	0.43	2.49	17	1
1:A:71:ASP:OD1	1:A:84:LYS:CB	0.43	2.67	7	1
1:A:95:HIS:CD2	1:A:95:HIS:H	0.43	2.32	11	1
1:A:72:PHE:CE2	1:A:81:SER:HA	0.43	2.47	3	1
1:A:119:VAL:CG1	1:A:120:SER:N	0.43	2.77	10	3
1:A:71:ASP:C	1:A:71:ASP:OD1	0.43	2.62	11	1
1:A:69:LEU:O	1:A:84:LYS:CB	0.43	2.67	6	1
1:A:68:ALA:CB	1:A:88:LEU:HB3	0.43	2.43	15	1
1:A:72:PHE:HZ	1:A:79:THR:HG23	0.43	1.72	15	1
1:A:69:LEU:HB2	1:A:117:THR:CG2	0.43	2.44	18	4
1:A:69:LEU:HG	1:A:117:THR:CG2	0.43	2.44	12	9
1:A:72:PHE:CG	1:A:81:SER:HA	0.42	2.49	3	1
1:A:90:VAL:CG2	1:A:116:ILE:HD13	0.42	2.44	4	1
1:A:91:LEU:HD12	1:A:103:GLN:NE2	0.42	2.28	18	1
1:A:84:LYS:C	1:A:84:LYS:CD	0.42	2.91	5	1
1:A:68:ALA:HB2	1:A:88:LEU:CB	0.42	2.40	15	2
1:A:90:VAL:CG2	1:A:111:VAL:CG1	0.42	2.98	14	1
1:A:119:VAL:HG12	1:A:120:SER:H	0.42	1.74	17	4
1:A:82:ILE:N	1:A:82:ILE:HD13	0.42	2.30	7	1
1:A:98:GLU:OE1	1:A:98:GLU:O	0.42	2.37	11	1
1:A:72:PHE:CE2	1:A:74:ALA:HB2	0.42	2.47	13	1
1:A:99:TRP:CE2	1:A:112:PRO:HB3	0.42	2.50	5	5
1:A:69:LEU:HD22	1:A:117:THR:HG21	0.42	1.90	18	1
1:A:72:PHE:CE1	1:A:81:SER:CB	0.42	3.03	3	1
1:A:71:ASP:O	1:A:115:TYR:CE1	0.42	2.73	6	1

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Clash(Å)	Distance(Å)	Models	
				Worst	Total
1:A:95:HIS:O	1:A:97:GLY:N	0.42	2.53	4	1
1:A:96:ASN:ND2	1:A:96:ASN:H	0.42	2.12	13	1
1:A:94:ASN:OD1	1:A:99:TRP:N	0.41	2.52	5	2
1:A:106:ASN:OD1	1:A:106:ASN:C	0.41	2.59	12	1
1:A:100:CYS:O	1:A:111:VAL:O	0.41	2.39	5	5
1:A:98:GLU:HG3	1:A:99:TRP:N	0.41	2.30	8	1
1:A:99:TRP:CZ3	1:A:112:PRO:CD	0.41	3.03	17	1
1:A:69:LEU:CD1	1:A:117:THR:HB	0.41	2.46	8	1
1:A:82:ILE:CD1	1:A:88:LEU:CD1	0.41	2.98	8	1
1:A:69:LEU:CA	1:A:117:THR:HG22	0.41	2.45	13	2
1:A:72:PHE:HB2	1:A:82:ILE:CD1	0.41	2.45	14	1
1:A:104:THR:C	1:A:106:ASN:N	0.41	2.77	15	3
1:A:106:ASN:O	1:A:106:ASN:CG	0.41	2.62	6	1
1:A:111:VAL:CG2	1:A:112:PRO:HD2	0.41	2.46	8	1
1:A:73:VAL:HG22	1:A:74:ALA:H	0.41	1.76	4	1
1:A:82:ILE:HD12	1:A:88:LEU:HD21	0.41	1.93	15	1
1:A:73:VAL:O	1:A:73:VAL:HG13	0.41	2.16	10	1
1:A:111:VAL:HG13	1:A:116:ILE:CD1	0.41	2.42	13	1
1:A:76:GLY:C	1:A:77:ASP:O	0.41	2.64	16	1
1:A:103:GLN:CG	1:A:108:GLN:CG	0.40	2.99	2	1
1:A:72:PHE:CD2	1:A:81:SER:HA	0.40	2.51	3	1
1:A:90:VAL:HG11	1:A:100:CYS:CB	0.40	2.46	12	1
1:A:101:GLU:OE2	1:A:109:GLY:O	0.40	2.39	15	1
1:A:91:LEU:CD1	1:A:103:GLN:OE1	0.40	2.59	16	1
1:A:84:LYS:CD	1:A:85:GLY:N	0.40	2.84	20	1
1:A:92:GLY:O	1:A:100:CYS:SG	0.40	2.79	13	1
1:A:65:LEU:HD23	1:A:89:ARG:HD3	0.40	1.93	4	1
1:A:77:ASP:OD2	1:A:78:ASN:OD1	0.40	2.40	13	1
1:A:65:LEU:C	1:A:65:LEU:CD1	0.40	2.95	14	1
1:A:74:ALA:HB2	1:A:81:SER:OG	0.40	2.17	14	1
1:A:90:VAL:CG1	1:A:93:TYR:CE1	0.40	3.04	15	1
1:A:103:GLN:CG	1:A:108:GLN:HG3	0.40	2.46	20	1

6.3 Torsion angles ⓘ

6.3.1 Protein backbone ⓘ

In the following table, the Percentiles column shows the percent Ramachandran outliers of the chain as a percentile score with respect to all PDB entries followed by that with respect to all NMR entries. The Analysed column shows the number of residues for which the backbone conformation was analysed and the total number of residues.

Mol	Chain	Analysed	Favoured	Allowed	Outliers	Percentiles	
1	A	55/62 (89%)	44±3 (80±5%)	8±3 (15±5%)	3±1 (5±2%)	2	22
All	All	1100/1240 (89%)	877 (80%)	165 (15%)	58 (5%)	2	22

All 12 unique Ramachandran outliers are listed below. They are sorted by the frequency of occurrence in the ensemble.

Mol	Chain	Res	Type	Models (Total)
1	A	85	GLY	10
1	A	78	ASN	8
1	A	119	VAL	8
1	A	95	HIS	6
1	A	77	ASP	5
1	A	74	ALA	5
1	A	96	ASN	5
1	A	97	GLY	4
1	A	84	LYS	2
1	A	94	ASN	2
1	A	76	GLY	2
1	A	73	VAL	1

6.3.2 Protein sidechains ⓘ

In the following table, the Percentiles column shows the percent sidechain outliers of the chain as a percentile score with respect to all PDB entries followed by that with respect to all NMR entries. The Analysed column shows the number of residues for which the sidechain conformation was analysed and the total number of residues.

Mol	Chain	Analysed	Rotameric	Outliers	Percentiles	
1	A	47/50 (94%)	31±3 (66±6%)	16±3 (34±6%)	1	11
All	All	940/1000 (94%)	619 (66%)	321 (34%)	1	11

All 40 unique residues with a non-rotameric sidechain are listed below. They are sorted by the frequency of occurrence in the ensemble.

Mol	Chain	Res	Type	Models (Total)
1	A	67	VAL	20
1	A	79	THR	20
1	A	82	ILE	20
1	A	117	THR	20
1	A	84	LYS	19
1	A	88	LEU	17

Continued on next page...

Continued from previous page...

Mol	Chain	Res	Type	Models (Total)
1	A	113	SER	14
1	A	105	LYS	14
1	A	69	LEU	14
1	A	87	LYS	12
1	A	94	ASN	12
1	A	98	GLU	10
1	A	86	GLU	9
1	A	71	ASP	9
1	A	108	GLN	9
1	A	93	TYR	9
1	A	111	VAL	8
1	A	91	LEU	8
1	A	66	PHE	7
1	A	114	ASN	7
1	A	95	HIS	6
1	A	89	ARG	6
1	A	104	THR	5
1	A	65	LEU	5
1	A	103	GLN	5
1	A	75	SER	4
1	A	96	ASN	4
1	A	77	ASP	4
1	A	101	GLU	3
1	A	120	SER	3
1	A	106	ASN	3
1	A	80	LEU	2
1	A	116	ILE	2
1	A	72	PHE	2
1	A	83	THR	2
1	A	119	VAL	2
1	A	100	CYS	2
1	A	115	TYR	1
1	A	78	ASN	1
1	A	81	SER	1

6.3.3 RNA ⓘ

There are no RNA molecules in this entry.

6.4 Non-standard residues in protein, DNA, RNA chains ⓘ

There are no non-standard protein/DNA/RNA residues in this entry.

6.5 Carbohydrates [i](#)

There are no oligosaccharides in this entry.

6.6 Ligand geometry [i](#)

There are no ligands in this entry.

6.7 Other polymers [i](#)

There are no such molecules in this entry.

6.8 Polymer linkage issues [i](#)

There are no chain breaks in this entry.

7 Chemical shift validation

No chemical shift data were provided